Slide 1: Defining the Future of Life-Saving Diagnostics at the Point of Care
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 2022 © 2022 Hyperfine, Inc.
Slide 2: Forward Looking Statements
Forward Looking Statements © 2022 Hyperfine, Inc. | Confidential and Proprietary This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine’s actual results may differ from its expectat
Slide 3: Preliminary Financial Information
Preliminary Financial Information © 2022 Hyperfine, Inc. | Confidential and Proprietary The preliminary financial information included in this presentation is unaudited and is subject to completion of Hyperfine’s quarter and year-end closing procedures and further financial review. In certain cases,
Slide 4: Brain diagnostics are single point-in-time; our mission
4 Today, brain diagnostics are single point-in-time and delay the time from door to discharge. Our mission is to transform patient care by creating access to life-saving diagnostics and actionable data at the point-of-care. © 2022 Hyperfine, Inc. | Confidential and Proprietary
Slide 5: The Hyperfine Ecosystem
The Hyperfine Ecosystem A full ecosystem solution: Hardware, software, consumables and applications powered by artificial intelligence Democratizing Imaging, Sensing, and Guided Intervention to cover the care continuum Sensing (in development) Imaging (FDA cleared) Intervention (exploratory) 13 © 20
Slide 6: Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption
Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption $23B $22B $28B Imaging Hospitals, Outpatient >100,000 Potential installation targets Sensing ICUs, Expanded Hospital, Surgical Centers, Outpatient, At-home ~4M Potential unit sales Guided Intervention Hospitals and Hea
Slide 7: We are Transforming Medical Imaging with Swoop
We are Transforming Medical Imaging with Swoop® Swoop is the world's first FDA-cleared portable MRI system™ MRI 1.0 1980 MRI 2.0 1990 MRI 3.0 FDA Cleared 2020 11 © 2022 Hyperfine, Inc. | Confidential and Proprietary
Slide 8: Swoop is the Next Generation of MRI
Swoop® is the Next Generation of MRI Installed base of 70 units* as of year-end 2021 Current primary clinical uses: Hydrocephalus and Pediatrics Neuro ICU Follow-Up and Post-Operative Stroke Portable low-field MRI Patent protected noise cancellation system enables clinical-grade images FDA Cleared i
Slide 9: Swoop Brings MRI to the Patient Acute Care Settings
Swoop® Brings MRI to the Patient 16 Acute Care Settings Swoop is designed to enable rapid diagnoses and treatment for patients regardless of income, resources, or location Produces high-quality images at low magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients W
Slide 10: Clinical & Workflow Benefits
Clinical & Workflow Benefits
Slide 11: Numerous challenges with conventional MRI
Numerous challenges 14 Adverse events occur in 22-46% of cases during transport with conventional MRI : High-cost limits accessibility Complex site requirements and upgrades Scheduling delays lead to longer length of stay Consumption of valuable personnel resources Risk of adverse events during tran
Slide 12: Hyperfine Workflow Benefits
Hyperfine Workflow Benefits 15 MRI ordered Patient preparation Intra-hospital transfer to MRI MRI examination Intra-hospital transfer to unit Post MRI examination Traditional MRI workflow (25.8 hours) MRI ordered MRI examination Post MRI examination Hyperfine workflow (90 mins, 94% reduction in tota
Slide 13: Swoop Clinical Use Cases Today
© 2021 HYPERFINE Intensive Care Unit Acute Mental Status Change Ataxia Cerebral Edema Cerebrovascular Disease Cranial Neuropathy Extra Ventricular Drain Placement Follow-up Intracranial Hemorrhage Follow-up Ischemic Stroke Follow-up Hematoma Stroke Tumor Pre- and Post-Op Emergency Department Blurred
Slide 14: Clinical Validation of Hyperfine
Clinical Validation of Hyperfine 20 Game changer is a good way to put it […] being able to do the level of sophisticated imaging in an ICU that MRI can provide.’’ Dr. Fady Charbel, MD, FAANS, FACS Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and
Slide 15: Use Case: Stroke
Use Case: Stroke HYPERFINE
Slide 16: Hyperfine Provides Compelling Platform for Stroke Diagnosis
Hyperfine Provides Compelling Platform for Stroke Diagnosis 15 million people worldwide suffer a stroke annually Stroke is the 2nd leading cause of death globally 87% strokes are ischemic strokes MRI scans are better at detecting ischemic stroke damage compared to CT scans MRI use for stroke has bee
Slide 17: Stroke Diagnosis Confirmed
Stroke Diagnosis Confirmed 62-year-old male Presented with new left sided weakness and tremor © 2022 Hyperfine, Inc. | Confidential and Proprietary
Slide 18: Use Case: Hydrocephalus
Use Case: Hydrocephalus HYPERFINE
Slide 19: Pediatric Hydrocephalus Management is a Huge Problem
Pediatric Hydrocephalus Management is a Huge Problem ~400,000 hospital days, $2B in hospital charges in the US Children with hydrocephalus need life-long monitoring and use a disproportionate number of hospital days and resources.1, 2 Any symptoms cause trips to hospital for a shunt check to ensure
Slide 20: Personal Stories from the Hydrocephalus Association
Personal Stories from the Hydrocephalus Association Vacations can involve traveling with CD’s and notebooks with prior scans. At home, we keep a suitcase packed to keep our child entertained during the long wait time in the ED for imaging and hospital stay. Received so many CT scans that w e’re wait
Slide 21: Hydrocephalus Workflow Improvement with Swoop
Hydrocephalus Workflow Improvement with Swoop® Traditional workflow results in delayed diagnosis and potential radiation exposure Hyperfine allows kids to be imaged sooner, next to their loved ones, without radiation Patient preparation Transfer to imaging Fast MRI or CT Transfer to unit Diagnosis an
Slide 22: Hydrocephalus: Swoop's Potential from Early Cases
Hydrocephalus: Swoop’s Potential from Early Cases Hyperfine is an excellent addition to the neurosurgery clinic for screening of hydrocephalus patients. The convenience for the patient, reduced scan time, and cost of the machine make this a device that should be considered for any neurosurgery clini
Slide 23: Use Case: ICU Serial Imaging
Use Case: ICU Serial Imaging HYPERFINE
Slide 24: Patient Delays to Transfer in the ICU Create Major Unnecessary Costs
Patient Delays to Transfer in the ICU Creates Major Unnecessary Costs for Hospitals, is “Common and Costly” Estimated $300/hr for delays, >$22,000/week for hospital (>$1M/year) for large academic center Imaging capabilities of MRI, CT and Ultrasound should be available 24/7/365 at all facilities. In
Slide 25: Current ICU Imaging Workflow with Conventional MRI
Current ICU Imaging Workflow with Conventional MRI Patient preparation Intra-hospital transfer to MRI MRI examination Intra-hospital transfer to unit Post MRI examination Traditional MRI workflow can lead to prolonged delays in patient care and higher resources consumption MRI ordered Patient unstable
Slide 26: Improved ICU Imaging Workflow with Swoop
MRI ordered MRI examination Post MRI examination Portable MRI workflow enables timely care for earlier discharge by bringing brain imaging to the patient’s bedside Faster Transfer from ICU Faster Treatment Continue monitoring with Improved ICU Imaging Workflow with Swoop © 2022 Hyperfine, Inc. | Confi
Slide 27: Swoop's Potential Benefits in the ICU
Swoop’s Potential Benefits in the ICU Reduced adverse events associated with patient transport © 2022 Hyperfine, Inc. | Confidential and Proprietary Adverse events occur in up to 46% of transported patients. Reduced costs associated with length of stay Shortening time to diagnosis, avoiding interrupt
Slide 28: Clinical Settings Growth
Clinical Settings Growth ~2000 ICU’s (Adult, neuro) ~1000 Neonatal ICU ~5830 Emergency Departments ~1250 Operating Rooms and Angio Suites ~220 Children’s Hospitals ~115 Neuro ICU’s Today’s use cases provide a sizeable opportunity and platform for growth. © 2022 Hyperfine, Inc. | Confidential and Pro
Slide 29: Pipeline Opportunities
Pipeline Opportunities HYPERFINE
Slide 30: Innovative R&D Engine Designed to Expand Product Roadmap
Innovative R&D Engine Designed to Expand Product Roadmap 24 Stroke Hydrocephalus Extremities Intra and Post Operative Expanded Addressable Market Improved usability Automated Stroke Detection Lower cost of goods Existing applications V1 Potential future applications V2 C-spine Potential benefits: ©
Slide 31: Developing a Non-Invasive Brain Vital Sensor
Developing a Non-Invasive Brain Vital Sensor Breakthrough AEGTM Technology designed to unlock access to blood flow and pressure Non-Invasive Non-invasive use on every patient to enable broader access and earlier diagnosis Continuous Trend Analysis Designed for continuous sensing to build trends for
Slide 32: Brain-Sensing Clinical Opportunities
Brain-Sensing Clinical Opportunities 27 Intensive Care Unit Emergency Department Operating Room Outpatient & At Home Hydrocephalus Vasospasm Stroke Cerebral edema Traumatic Brain Injury Subarachnoid hemorrhage Suspected seizures Acute liver failure Altered mental status Brain tumors Sepsis - Intraop
Slide 33: Financial Profile
Financial Profile
Slide 34: 2021 Preliminary Financial Results & Total Installed Units
2021 Preliminary Financial Results* & Total Installed Units Approximately $1.42 to $1.50 million preliminary unaudited 2021 total revenue Realized approximately $1.45 million in grant funding for the full year 2021 as part of grant fulfillment for Swoop installations *See slide above titled “Prelimi
Slide 35: 2021 & 2022: Major Accomplishments
2021 & 2022: Major Accomplishments © 2022 Hyperfine, Inc. | Confidential and Proprietary July 2021: Announced Definitive Agreement to be Listed on Nasdaq through a Business Combination with HealthCor Catalio Acquisition Corp. August 2021: Swoop® Demonstrates High Accuracy for Detection of Brain Hemo
Slide 36: © 2022 Hyperfine, Inc. | Confidential and Proprietary
© 2022 Hyperfine, Inc. | Confidential and Proprietary
Slide 37: Leadership Team
Leadership Team HYPERFINE
Slide 38: Management Team with Proven Track Record of Success
Management Team with Proven Track Record of Success 35 Dave Scott Chief Executive Officer Alok Gupta Chief Financial Officer Dr. Khan Siddiqui Chief Strategy Officer & Chief Medical Officer Tom Teisseyre Chief Product Officer Mark Hughes Chief Operating Officer Scott White Chief Commercial Officer K
Slide 39: Thank You!
Thank You! HYPERFINE
Slide 40: Appendix
Appendix HYPERFINE
Slide 41: Brain is the Largest MRI Market with Nearly 25% of MR Procedures
Brain is the Largest MRI Market with Nearly 25% of MR Procedures N = 27.4 Million Procedures MR Procedure Mix, All Sites, by Percent, 2020 Distribution of MR Sites and Procedures, by Site Type, 2020 3,025 1,765 445 1,000 2,930 8.4 1.8 5.0 6.8 5.4 Spine Breast Chest Pelvis & Abdomen (including liver)